Company intelligence / Profile preview
Achilles Therapeutics plc
London, United Kingdomachillestx.com ↗
- Ownership
- Public · ACHL
- Employees
- ~215
- Development stage
- Other
01
Overview
The company discontinued its TIL-based cNeT program and closed Phase I/IIa CHIRON and THETIS clinical trials in September 2024 as they did not meet goals for commercial viability. The company entered liquidation in March 2025.
- Therapeutic areas
- Oncology
- Modalities
- T cell therapiesTIL-based therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Arcturus Therapeutics (research pact established in May 2024)
Beyond the preview
Go deeper on Achilles Therapeutics plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Achilles Therapeutics plc.